SCHEMBL143838

SCHEMBL143838

COC(=O)c1c(O)cc(=O)[nH]c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
ACHE P22303 1/20 0.46
CYP1A2 P05177 1/20 0.46
CA12 O43570 5/20 0.44
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA7 P43166 5/20 0.44
CA9 Q16790 5/20 0.44
CA14 Q9ULX7 5/20 0.44
HPGD P15428 2/20 0.44
GAA P10253 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
XDH P47989 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640595 0.82 CYP3A4 (0.49) CYP3A4ACHECYP1A2CA12CA1
SCHEMBL21416048 0.82 KDM4E (0.59) CYP3A4CYP1A2CA12CA1CA2
SCHEMBL27980095 0.81 CYP3A4 (0.51) CYP3A4ACHECYP1A2CA12CA1
SCHEMBL21416134 0.78 ALDH1A1 (0.39) CYP3A4ACHECA12CA1CA2
SCHEMBL1328619 0.76 CYP3A4 (0.42) CYP3A4ACHECYP1A2CA12CA1
SCHEMBL13743871 0.70 KDM4E (0.71) CYP3A4ACHECYP1A2CA12CA1
SCHEMBL725269 0.69 CYP3A4 (0.77) CYP3A4ACHECA12CA1CA2
SCHEMBL1636307 0.67 CYP3A4 (0.62) CYP3A4ACHECA12CA1CA2
SCHEMBL8549690 0.67 CYP3A4 (0.47) CYP3A4ACHECA12CA1CA2
SCHEMBL22491120 0.67 GAA (0.50) CYP3A4ACHECA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119510615-A Detection method for specific impurities in Enalastat S1 intermediate 扬州市普林斯医药科技有限公司 2025-02-25 CN claimed
CN-119510615-A Detection method for specific impurities in Enalastat S1 intermediate 扬州市普林斯医药科技有限公司 2025-02-25 CN disclosed
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 CN disclosed
US-11434238-B2 Method for producing triazolopyridine compound JAPAN TOBACCO INC. (JP) 2022-09-06 US disclosed
CN-110214139-B Process for producing triazolopyridine compound 日本烟草产业株式会社 2022-08-23 CN disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND SHIONOGI & CO., LTD. (JP) 2020-10-29 US disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US disclosed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 EP disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 WO disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND EPOR, PAH, THPO CYP3A4 2987/4885ACHE 4262/4885CYP1A2 1234/4885
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 CYP3A4 3575/4885ACHE 1100/4885CYP1A2 3571/4885
US-11434238-B2 Method for producing triazolopyridine compound EPOR, PAH, THPO CYP3A4 2987/4885ACHE 4262/4885CYP1A2 1234/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP3A4 3427/4885ACHE 1511/4885CYP1A2 3585/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 CYP3A4 4834/4885ACHE 4355/4885CYP1A2 4765/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 CYP3A4 3575/4885ACHE 1100/4885CYP1A2 3571/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP3A4 3575/4885ACHE 1100/4885CYP1A2 3571/4885
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP3A4 1385/4885ACHE 2086/4885CYP1A2 2072/4885
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 CYP3A4 4834/4885ACHE 4355/4885CYP1A2 4765/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP3A4 3427/4885ACHE 1511/4885CYP1A2 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.